TCM
SRNE

Tekla Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Tekla Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-142,597
Closed -$1.65M – 134
2015
Q1 		$1.65M Sell
142,597
-71,299
-33% -$825K 0.07% 108
2014
Q4 		$2.15M Buy
+213,896
New +$1.08M 0.1% 84

Other funds holding SRNE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tekla Capital Management's SRNE Position: Q2 2015 in Review

Tekla Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2015, closing a stake of 142,597 shares — an estimated $1.65M sold.

Tekla Capital Management first reported a position in SRNE in Q4 2014 and held it in 2 quarters. The position peaked at $2.15M in Q4 2014. 75 funds tracked by Wall St. Rank hold SRNE as of Q2 2015.

  • Tekla Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Tekla Capital Management sold 142,597 Sorrento Therapeutics, Inc. shares in Q2 2015, an estimated $1.65M.
  • Tekla Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Tekla Capital Management's Sorrento Therapeutics, Inc. position peaked at $2.15M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2015.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.